Literature DB >> 25775064

Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye.

Yinin Hu1, Patrick D Melmer, Craig L Slingluff.   

Abstract

OBJECTIVE: The purpose of this study was to assess regional recurrence rates of patients who underwent sentinel lymph node biopsy (SLNB) using radiocolloid guidance alone.
BACKGROUND: Isosulfan blue dye is commonly used along with Tc99-labeled radiocolloid localization in SLNB for melanoma. Blue dye has, however, been associated with allergic reactions, long-term staining of skin, and increased cost. We hypothesized that the rate of regional recurrence when SLNB is performed with radiocolloid alone would be comparable to established reports using both radiocolloid and blue dye.
METHODS: A prospectively collected database was retrospectively queried for patients who underwent SLNB for melanoma during the years 2005 through 2008. Data collected included patient demographics, primary lesion characteristics, operative details, and recurrence. The primary outcome was the rate of recurrence within the biopsied basin after negative SLNB's performed without isosulfan blue dye.
RESULTS: In 215 patients, 279 nodal basins were identified. All patients underwent successful radiocolloid localization, and positive sentinel nodes were found in 40 patients (18.6%). Six of 175 patients with a negative SLNB developed a regional node recurrence as the first site of metastasis (3.4%). Among all 215 patients, 44 experienced recurrence of any kind (20.5%). Higher mitotic rate and Breslow depth were significantly associated with likelihood of recurrence.
CONCLUSIONS: Success rates, node positivity rates, and rates of regional recurrence after SLNB for melanoma using radiocolloid alone are acceptable and similar to those of prior reports using blue dye plus radiocolloid.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25775064      PMCID: PMC4568173          DOI: 10.1097/SLA.0000000000001187

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  39 in total

1.  Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping.

Authors:  M Bartolomei; A Testori; M Chinol; R Gennari; C De Cicco; L Leonardi; S Zoboli; G Paganelli
Journal:  Eur J Nucl Med       Date:  1998-11

2.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

3.  Multimodal Surgical Guidance during Sentinel Node Biopsy for Melanoma: Combined Gamma Tracing and Fluorescence Imaging of the Sentinel Node through Use of the Hybrid Tracer Indocyanine Green-(99m)Tc-Nanocolloid.

Authors:  Nynke S van den Berg; Oscar R Brouwer; Boudewijn E Schaafsma; Hanna M Mathéron; W Martin C Klop; Alfons J M Balm; Harm van Tinteren; Omgo E Nieweg; Fijs W B van Leeuwen; Renato A Valdés Olmos
Journal:  Radiology       Date:  2014-12-17       Impact factor: 11.105

4.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.

Authors:  J E Gershenwald; W Thompson; P F Mansfield; J E Lee; M I Colome; C H Tseng; J J Lee; C M Balch; D S Reintgen; M I Ross
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

6.  Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye.

Authors:  B A Kapteijn; O E Nieweg; I Liem; W J Mooi; A J Balm; S H Muller; J L Peterse; R A Valdés Olmos; C A Hoefnagel; B B Kroon
Journal:  Ann Surg Oncol       Date:  1997-03       Impact factor: 5.344

7.  Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid.

Authors:  J E Gershenwald; C H Tseng; W Thompson; P F Mansfield; J E Lee; M Bouvet; J J Lee; M I Ross
Journal:  Surgery       Date:  1998-08       Impact factor: 3.982

8.  Reliability of identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant melanoma.

Authors:  Stephan Ariyan; Charlotte Ariyan; Leonard R Farber; David S Fischer; Stuart D Flynn; Carolyn Truini
Journal:  J Am Coll Surg       Date:  2004-06       Impact factor: 6.113

Review 9.  Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review.

Authors:  Marco Gipponi; Carmine Di Somma; Alberto Peressini; Nicola Solari; Sara Gliori; Guido Nicolo; Federico Schenone; Paola Queirolo; Mario Roberto Sertoli; Ferdinando Cafiero
Journal:  J Surg Oncol       Date:  2004-03       Impact factor: 3.454

10.  Sentinel lymph node biopsy performed with local anesthesia in patients with early-stage breast carcinoma.

Authors:  Alberto Luini; Giovanna Gatti; Antonio Frasson; Paola Naninato; Cesare Magalotti; Paolo Arnone; Giuseppe Viale; Giancarlo Pruneri; Viviana Galimberti; Concetta De Cicco; Umberto Veronesi
Journal:  Arch Surg       Date:  2002-10
View more
  1 in total

Review 1.  Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma.

Authors:  Steven Morrison; Dale Han
Journal:  Curr Treat Options Oncol       Date:  2021-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.